CRP and coronary artery disorder: According to the FDA, rosuvastatin is currently approved as a drug that is able to lower the risk of stroke, myocardial infarction, and revascularization procedures in individuals who, on the one hand, have LDL cholesterol levels within normal limits and no clinically pronounced CHD, but on the other hand, have a high risk depending on age, CRP levels, and the presence of at least one additional risk factor for CVD.